

Stop Alzheimer's before it starts

Nature

547, 153-155

DOI: [10.1038/547153a](https://doi.org/10.1038/547153a)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Anti-A β single-chain variable fragment antibodies restore memory acquisition in a <i>Drosophila</i> model of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 11268.	1.6	13
2	β -Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View. <i>Molecules</i> , 2017, 22, 1692.	1.7	82
3	BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology. <i>Molecules</i> , 2017, 22, 1723.	1.7	89
4	Effect of solvent selectivity on crystallization-driven fibril growth kinetics of diblock copolymers. <i>Polymer</i> , 2018, 138, 359-362.	1.8	23
5	A solution NMR toolset to probe the molecular mechanisms of amyloid inhibitors. <i>Chemical Communications</i> , 2018, 54, 4644-4652.	2.2	33
6	Next generation antibody drugs: pursuit of the 'high-hanging fruit'. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 197-223.	21.5	595
7	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	3.1	79
8	Human Neurospheroid Arrays for In Vitro Studies of Alzheimer's Disease. <i>Scientific Reports</i> , 2018, 8, 2450.	1.6	98
9	A roadmap towards personalized immunology. <i>Npj Systems Biology and Applications</i> , 2018, 4, 9.	1.4	43
10	Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3 β Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New <i>C</i> -Glycosylflavones. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1166-1183.	1.7	32
11	Interaction between Ester-Type Tea Catechins and Neutrophil Gelatinase-Associated Lipocalin: Inhibitory Mechanism. <i>Journal of Agricultural and Food Chemistry</i> , 2018, 66, 1147-1156.	2.4	23
12	Amyloid-Beta Solubility in the Treatment of Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018, 378, 391-392.	13.9	39
13	NMR-driven identification of anti-amyloidogenic compounds in green and roasted coffee extracts. <i>Food Chemistry</i> , 2018, 252, 171-180.	4.2	47
14	The physics of polymer chain-folding. <i>Physics Reports</i> , 2018, 747, 1-50.	10.3	126
15	A sensitive detection assay based on signal amplification technology for Alzheimer's disease's early biomarker in exosome. <i>Analytica Chimica Acta</i> , 2018, 1022, 124-130.	2.6	38
16	Behavioral and psychological symptoms of dementia (BPSD) and impaired cognition reflect unsuccessful neuronal compensation in the pre-plaque stage and serve as early markers for Alzheimer's disease in the APP23 mouse model. <i>Behavioural Brain Research</i> , 2018, 347, 300-313.	1.2	20
17	Traced on the Timeline: Discovery of Acetylcholine and the Components of the Human Cholinergic System in a Primitive Unicellular Eukaryote <i>Acanthamoeba</i> spp.. <i>ACS Chemical Neuroscience</i> , 2018, 9, 494-504.	1.7	18
18	Amyloid- β and tau complexity " towards improved biomarkers and targeted therapies. <i>Nature Reviews Neurology</i> , 2018, 14, 22-39.	4.9	303

#	ARTICLE	IF	CITATIONS
19	Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 193-201.	1.4	5
20	Genetics of Parkinson's disease and related disorders. <i>Journal of Medical Genetics</i> , 2018, 55, 73-80.	1.5	55
21	The Ethyl Acetate Extract of Leaves of <i>Ugni molinae</i> Turcz. Improves Neuropathological Hallmarks of Alzheimer's Disease in Female APP ^{swe} /PS1 ^{dE9} Mice Fed with a High Fat Diet. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1175-1191.	1.2	10
22	Gradual Disturbances of the Amplitude of Low-Frequency Fluctuations (ALFF) and Fractional ALFF in Alzheimer Spectrum. <i>Frontiers in Neuroscience</i> , 2018, 12, 975.	1.4	135
23	Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer's disease. <i>International Journal of Molecular Medicine</i> , 2019, 43, 956-966.	1.8	48
24	Advances in Resting State Neuroimaging of Mild Cognitive Impairment. <i>Frontiers in Psychiatry</i> , 2018, 9, 671.	1.3	14
25	The Early Events That Initiate β -Amyloid Aggregation in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 359.	1.7	85
26	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. <i>Brain</i> , 2018, 141, 1917-1933.	3.7	1,008
27	Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. <i>Cell</i> , 2018, 173, 1073-1081.	13.5	765
28	Structure-activity relationships of β -hairpin mimics as modulators of amyloid β -peptide aggregation. <i>European Journal of Medicinal Chemistry</i> , 2018, 154, 280-293.	2.6	15
29	Amyloid- β /Drug Interactions from Computer Simulations and Cell-Based Assays. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S659-S672.	1.2	5
30	Impaired α -AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease. <i>Aging Cell</i> , 2018, 17, e12791.	3.0	58
31	Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 587-598.	1.5	27
32	A simple approach to quantitative determination of soluble amyloid- β peptides using a ratiometric fluorescence probe. <i>Biosensors and Bioelectronics</i> , 2019, 142, 111518.	5.3	19
33	Short amylin receptor antagonist peptides improve memory deficits in Alzheimer's disease mouse model. <i>Scientific Reports</i> , 2019, 9, 10942.	1.6	25
35	Age-Linked Non-Transmissible Diseases. <i>Practical Issues in Geriatrics</i> , 2019, , 59-82.	0.3	0
36	Alzheimer's disease: Key developments support promising perspectives for therapy. <i>Pharmacological Research</i> , 2019, 146, 104316.	3.1	17
37	Investigational BACE inhibitors for the treatment of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 967-975.	1.9	94

#	ARTICLE	IF	CITATIONS
38	Brain Structural Correlates of Odor Identification in Mild Cognitive Impairment and Alzheimer's Disease Revealed by Magnetic Resonance Imaging and a Chinese Olfactory Identification Test. <i>Frontiers in Neuroscience</i> , 2019, 13, 842.	1.4	20
39	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. <i>Alzheimer's and Dementia</i> , 2019, 15, 1448-1457.	0.4	7
40	Protective roles of isoastilbin against Alzheimer's disease via Nrf2-mediated antioxidation and anti-apoptosis. <i>International Journal of Molecular Medicine</i> , 2019, 43, 1406-1416.	1.8	18
41	Seeding and Cross-Seeding Aggregations of A β_{40} and Its N-Terminal-Truncated Peptide A β_{1-40} . <i>Langmuir</i> , 2019, 35, 2821-2831.	1.6	13
42	The Potential Role of Dysregulated miRNAs in Alzheimer's Disease Pathogenesis and Progression. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1123-1145.	1.2	13
43	Computational design and evaluation of β -sheet breaker peptides for destabilizing Alzheimer's amyloid β_{42} protofibrils. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 17935-17950.	1.2	16
44	Plasma MicroRNAs Are Altered Early and Consistently in a Mouse Model of Tauopathy. <i>Neuroscience</i> , 2019, 411, 164-176.	1.1	4
46	Age at onset in genetic prion disease and the design of preventive clinical trials. <i>Neurology</i> , 2019, 93, e125-e134.	1.5	73
47	Overview of novel multifunctional agents based on conjugates of β^3 -carbolines, carbazoles, tetrahydrocarbazoles, phenothiazines, and aminoadamantanes for treatment of Alzheimer's disease. <i>Chemico-Biological Interactions</i> , 2019, 308, 224-234.	1.7	36
48	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 27.	3.0	82
49	Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 845-847.	1.3	4
50	Early-Stage Identification and Pathological Development of Alzheimer's Disease Using Multimodal MRI. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1013-1027.	1.2	41
51	Design and sample size considerations for Alzheimer's disease prevention trials using multistate models. <i>Clinical Trials</i> , 2019, 16, 111-119.	0.7	15
52	Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7793-7798.	3.3	41
53	Impaired Spatial Reorientation in the 3xTg-AD Mouse Model of Alzheimer's Disease. <i>Scientific Reports</i> , 2019, 9, 1311.	1.6	24
54	GABA-containing compound gammapyrone protects against brain impairments in Alzheimer's disease model male rats and prevents mitochondrial dysfunction in cell culture. <i>Journal of Neuroscience Research</i> , 2019, 97, 708-726.	1.3	55
55	Multi-angles of smoking and mild cognitive impairment: is the association mediated by sleep duration?. <i>Neurological Sciences</i> , 2019, 40, 1019-1027.	0.9	10
56	Predictive Value of Routine Peripheral Blood Biomarkers in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 332.	1.7	46

#	ARTICLE	IF	CITATIONS
57	Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 93-97.	1.9	5
58	Microglia metabolism in health and disease. <i>Neurochemistry International</i> , 2019, 130, 104331.	1.9	56
59	On the role of synthesized hydroxylated chalcones as dual functional amyloid- β^2 aggregation and ferroptosis inhibitors for potential treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2019, 166, 11-21.	2.6	74
60	bioNMR-based identification of natural anti-A β^2 compounds in <i>Peucedanum ostruthium</i> . <i>Bioorganic Chemistry</i> , 2019, 83, 76-86.	2.0	26
61	Reduced brain amyloid burden in elderly patients with narcolepsy type 1. <i>Annals of Neurology</i> , 2019, 85, 74-83.	2.8	18
62	Evaluating the Benefits of the TimeSlips Creative Storytelling Program for Persons With Varying Degrees of Dementia Severity. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 163-170.	0.9	19
63	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH's EXAMINER as a potential clinical trial endpoint. <i>Alzheimer's and Dementia</i> , 2020, 16, 11-21.	0.4	32
64	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 37-48.	0.4	38
65	The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development. <i>New Genetics and Society</i> , 2020, 39, 101-126.	0.7	8
66	Frequency-dependent changes in fractional amplitude of low-frequency oscillations in Alzheimer's disease: a resting-state fMRI study. <i>Brain Imaging and Behavior</i> , 2020, 14, 2187-2201.	1.1	52
67	Real-time BODIPY Binding Assay To Screen Inhibitors of the Early Oligomerization Process of A β^2 1-42 Peptide. <i>ChemBioChem</i> , 2020, 21, 1129-1135.	1.3	17
68	Strengthened theta-burst transcranial magnetic stimulation as an adjunctive treatment for Alzheimer's disease: An open-label pilot study. <i>Brain Stimulation</i> , 2020, 13, 484-486.	0.7	20
69	Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APP ^{swE} /PS1 ^{dE9} Mice. <i>Molecular Neurobiology</i> , 2020, 57, 1814-1827.	1.9	51
70	Notopterygium incisum extract (NRE) rescues cognitive deficits in APP/PS1 Alzheimer's disease mice by attenuating amyloid-beta, tau, and neuroinflammation pathology. <i>Journal of Ethnopharmacology</i> , 2020, 249, 112433.	2.0	19
71	Dampened Slow Oscillation Connectivity Anticipates Amyloid Deposition in the PS2APP Mouse Model of Alzheimer's Disease. <i>Cells</i> , 2020, 9, 54.	1.8	17
72	14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2020, 40, 8188-8203.	1.7	25
73	Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. <i>Nature Neuroscience</i> , 2020, 23, 1580-1588.	7.1	53
74	Microglia: Agents of the CNS Pro-Inflammatory Response. <i>Cells</i> , 2020, 9, 1717.	1.8	174

#	ARTICLE	IF	CITATIONS
75	Lower brain-derived neurotrophic factor levels are associated with age-related memory impairment in community-dwelling older adults: the Sefuri study. <i>Scientific Reports</i> , 2020, 10, 16442.	1.6	33
76	The efficacy and safety of hachimijiogan for mild Alzheimer disease in an exploratory, open standard treatment controlled, randomized allocation, multicenter trial. <i>Medicine (United States)</i> , 2020, 99, e22370.	0.4	3
77	Impact of Mutations on the Conformational Transition from α -Helix to β -Sheet Structures in Arctic-Type $A\beta_{40}$: Insights from Molecular Dynamics Simulations. <i>ACS Omega</i> , 2020, 5, 23219-23228.	1.6	6
78	Potential human transmission of amyloid β pathology: surveillance and risks. <i>Lancet Neurology</i> , The, 2020, 19, 872-878.	4.9	46
79	Deciphering inhibitory activity of flavonoids against tau protein kinases: a coupled molecular docking and quantum chemical study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 411-424.	2.0	12
80	Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, S91-S107.	1.2	13
81	Astaxanthin Ameliorated Parvalbumin-Positive Neuron Deficits and Alzheimer's Disease-Related Pathological Progression in the Hippocampus of AppNL-G-F/NL-G-F Mice. <i>Frontiers in Pharmacology</i> , 2020, 11, 307.	1.6	27
82	Dynamic network connectivity predicts subjective cognitive decline: the Sino-Longitudinal Cognitive impairment and dementia study. <i>Brain Imaging and Behavior</i> , 2020, 14, 2692-2707.	1.1	16
83	The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. <i>Molecular Psychiatry</i> , 2021, 26, 6023-6037.	4.1	40
84	<p>Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial</p>. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 743-754.	1.3	9
85	Impaired Hippocampal-Cortical Interactions during Sleep in a Mouse Model of Alzheimer's Disease. <i>Current Biology</i> , 2020, 30, 2588-2601.e5.	1.8	32
86	A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing β -Site Amyloid Precursor Protein Cleaving Enzyme 1's Expression and H ₂ O ₂ -Induced Cytotoxicity in SH-SY5Y Cells. <i>Neurochemical Research</i> , 2020, 45, 2113-2127.	1.6	2
87	Towards a treatment for genetic prion disease: trials and biomarkers. <i>Lancet Neurology</i> , The, 2020, 19, 361-368.	4.9	60
88	Rivastigmine modifies the β -secretase pathway and potentially early Alzheimer's disease. <i>Translational Psychiatry</i> , 2020, 10, 47.	2.4	44
89	Effect of Piedmont mutation (L34V) on the structure, dynamics, and aggregation of Alzheimer's $A\beta_{40}$ peptide. <i>Journal of Molecular Graphics and Modelling</i> , 2020, 97, 107571.	1.3	8
90	Is Sleep Disruption a Cause or Consequence of Alzheimer's Disease? Reviewing Its Possible Role as a Biomarker. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1168.	1.8	39
91	Circulating Exosomal miRNA as Diagnostic Biomarkers of Neurodegenerative Diseases. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 53.	1.4	90
92	Pharmaceutical applications of organofluorine compounds. , 2020, , 133-214.		0

#	ARTICLE	IF	CITATIONS
93	Circulating MicroRNAs as Diagnostic Biomarkers for Motor Neuron Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 354.	1.4	8
94	Biological sex and DNA repair deficiency drive Alzheimer's disease via systemic metabolic remodeling and brain mitochondrial dysfunction. <i>Acta Neuropathologica</i> , 2020, 140, 25-47.	3.9	45
95	Analysis of the Human Plasma Proteome Using Multi-Nanoparticle Protein Corona for Detection of Alzheimer's Disease. <i>Advanced Healthcare Materials</i> , 2021, 10, e2000948.	3.9	19
96	Usnic acid enantiomers restore cognitive deficits and neurochemical alterations induced by A β 42 in mice. <i>Behavioural Brain Research</i> , 2021, 397, 112945.	1.2	12
97	NMR-based Lavado cocoa chemical characterization and comparison with fermented cocoa varieties: Insights on cocoa's anti-amyloidogenic activity. <i>Food Chemistry</i> , 2021, 341, 128249.	4.2	15
98	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. <i>Alzheimer's and Dementia</i> , 2021, 17, 605-617.	0.4	17
99	The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1331, 31-48.	0.8	2
100	Fluoxetine Promotes Hippocampal Oligodendrocyte Maturation and Delays Learning and Memory Decline in APP/PS1 Mice. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 627362.	1.7	13
102	Sheet breakers with consecutive phenylalanines: Insights into mechanism of dissolution of amyloid fibrils. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 762-780.	1.5	4
103	Effect of memantine, an anti-Alzheimer's drug, on rodent microglial cells in vitro. <i>Scientific Reports</i> , 2021, 11, 6151.	1.6	5
104	Early detection of amyloid load using 18F-florbetaben PET. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 67.	3.0	26
105	Early intervention attenuates synaptic plasticity impairment and neuroinflammation in 5xFAD mice. <i>Journal of Psychiatric Research</i> , 2021, 136, 204-216.	1.5	18
106	Alzheimer's Disease Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4805.	1.8	13
107	An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band. <i>Current Alzheimer Research</i> , 2021, 18, 45-55.	0.7	14
108	Recent Progress in the Drug Development for the Treatment of Alzheimer's Disease Especially on Inhibition of Amyloid-peptide Aggregation. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 969-990.	1.1	6
109	Tau Pathology Profile Across a Parietal-Hippocampal Brain Network Is Associated With Spatial Reorientation Learning and Memory Performance in the 3xTg-AD Mouse. <i>Frontiers in Aging</i> , 2021, 2, .	1.2	5
110	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
111	Design, synthesis, and biological evaluation of diosgenin-indole derivatives as dual-functional agents for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2021, 219, 113426.	2.6	20

#	ARTICLE	IF	CITATIONS
112	Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 694329.	1.1	8
113	Connectome-based model predicts episodic memory performance in individuals with subjective cognitive decline and amnesic mild cognitive impairment. <i>Behavioural Brain Research</i> , 2021, 411, 113387.	1.2	9
114	An early proinflammatory transcriptional response to tau pathology is age-specific and foreshadows reduced tau burden. <i>Brain Pathology</i> , 2022, 32, e13018.	2.1	7
115	Improved modeling of human AD with an automated culturing platform for iPSC neurons, astrocytes and microglia. <i>Nature Communications</i> , 2021, 12, 5220.	5.8	38
116	1H-1,2,3-triazole grafted tacrine-chalcone conjugates as potential cholinesterase inhibitors with the evaluation of their behavioral tests and oxidative stress in mice brain cells. <i>Bioorganic Chemistry</i> , 2021, 114, 105053.	2.0	16
117	Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 589-597.	0.4	25
118	A Perspective on Multi-target Drugs for Alzheimer's Disease. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 434-445.	4.0	148
120	Current Trends in the Development of Drugs for the Treatment of Alzheimer's Disease and their Clinical Trials. <i>Biomedical Chemistry Research and Methods</i> , 2018, 1, e00015.	0.1	7
121	Potential Use of Nanomedicine for the Anti-inflammatory Treatment of Neurodegenerative Diseases. <i>Current Pharmaceutical Design</i> , 2018, 24, 1589-1616.	0.9	21
122	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 1286-1299.	0.9	12
123	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 177-191.	1.8	17
124	Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease. <i>Neural Regeneration Research</i> , 2019, 14, 1721.	1.6	2
125	Enhanced Expression of microRNA-1273g-3p Contributes to Alzheimer's Disease Pathogenesis by Regulating the Expression of Mitochondrial Genes. <i>Cells</i> , 2021, 10, 2697.	1.8	10
128	Functional characterization of multifunctional ligands targeting acetylcholinesterase and alpha 7 nicotinic acetylcholine receptor. <i>Biochemical Pharmacology</i> , 2020, 177, 114010.	2.0	6
129	Application for Decision-Making on Mild Cognitive Impairments. <i>Engineering Proceedings</i> , 2021, 7, 55.	0.4	0
130	Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer's disease. <i>Journal of Innovative Optical Health Sciences</i> , 2022, 15, .	0.5	9
131	Promising molecular targets for pharmacological therapy of neurodegenerative pathologies. <i>Acta Naturae</i> , 2020, 12, 60-80.	1.7	3
132	Accelerated intermittent theta-burst stimulation broadly ameliorates symptoms and cognition in Alzheimer's disease: A randomized controlled trial. <i>Brain Stimulation</i> , 2022, 15, 35-45.	0.7	28

#	ARTICLE	IF	CITATIONS
133	Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay. <i>Journal of Nanobiotechnology</i> , 2021, 19, 366.	4.2	14
134	Essential Oils from Spices Inhibit Cholinesterase Activity and Improve Behavioral Disorder in Aβ ₁₋₄₂ Induced Dementia. <i>Chemistry and Biodiversity</i> , 2021, , e2100443.	1.0	10
135	Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ ₁₋₄₂ Leading to Mild Cognitive Impairment in AAV-AD Rats. <i>Journal of prevention of Alzheimer's disease</i> , The, 0, , 1.	1.5	4
136	Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective. <i>Animal Models and Experimental Medicine</i> , 2022, 5, 27-37.	1.3	10
137	Abnormal characterization of dynamic functional connectivity in Alzheimer's disease. <i>Neural Regeneration Research</i> , 2022, 17, 2014.	1.6	29
138	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 2687-2698.	0.4	13
139	Conjugates of Tacrine with Salicylamide as Promising Multitarget Agents for Alzheimer's Disease. <i>ChemMedChem</i> , 2022, 17, e202200080.	1.6	11
140	Progress and Development of Carbazole Scaffold Based as Potential Anti- Alzheimer Agents Using MTDL Approach. <i>Letters in Drug Design and Discovery</i> , 2022, 19, 1049-1067.	0.4	3
141	Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future. <i>Ageing Research Reviews</i> , 2022, 77, 101612.	5.0	26
142	The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy. <i>Cells</i> , 2022, 11, 16.	1.8	17
144	Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers. <i>Neurotherapeutics</i> , 2022, 19, 209-227.	2.1	36
145	The potential of polygenic scores to improve cost and efficiency of clinical trials. <i>Nature Communications</i> , 2022, 13, .	5.8	19
146	Synthesis and preliminary biological evaluation of new phthalazinone derivatives with PARP-1 and cholinesterase inhibitory activities. <i>Letters in Drug Design and Discovery</i> , 2022, 19, .	0.4	0
148	DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2023, 30, 669-688.	1.2	8
149	NMR-Driven Identification of Cinnamon Bud and Bark Components With Anti-Aβ ₁₋₄₂ Activity. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	6
150	Textural features reflecting local activity of the hippocampus improve the diagnosis of Alzheimer's disease and amnesic mild cognitive impairment: A radiomics study based on functional magnetic resonance imaging. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	6
151	Sleep duration and biomarkers of inflammation in African American and white participants with a parental history of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	1.8	4
152	Dissecting the Inhibitory Mechanism of the Aβ ₁₋₄₂ -Crystallin Domain against Aβ ₁₋₄₂ Aggregation and Its Effect on Aβ ₁₋₄₂ Protofibrils: A Molecular Dynamics Simulation Study. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2842-2851.	1.7	3

#	ARTICLE	IF	CITATIONS
153	Anticholinesterase Compounds from Endemic <i>Prangos uechtrizii</i> . <i>Chemistry and Biodiversity</i> , 2022, 19, .	1.0	2
154	Photobiomodulation and visual stimulation against cognitive decline and Alzheimer's disease pathology: A systematic review. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	1.8	5
155	Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
156	Association of lower liver function with cognitive impairment in the Shenzhen ageing-related disorder cohort in China. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	2
157	An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer's disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
158	Identification of a Hydroxygallic Acid Derivative, Zingibroside R1 and a Sterol Lipid as Potential Active Ingredients of <i>Cuscuta chinensis</i> Extract That Has Neuroprotective and Antioxidant Effects in Aged <i>Caenorhabditis elegans</i> . <i>Nutrients</i> , 2022, 14, 4199.	1.7	4
159	Alzheimer's Disease Prevention through Natural Compounds: Cell-Free, In Vitro, and In Vivo Dissection of Hop (<i>Humulus lupulus</i> L.) Multitarget Activity. <i>ACS Chemical Neuroscience</i> , 2022, 13, 3152-3167.	1.7	4
160	Unravelling the relationship between amyloid accumulation and brain network function in normal aging and very mild cognitive decline: a longitudinal analysis. <i>Brain Communications</i> , 2022, 4, .	1.5	3
161	HSI-LFS-BERT: Novel Hybrid Swarm Intelligence Based Linguistics Feature Selection and Computational Intelligent Model for Alzheimer's Disease Prediction Using Audio Transcript. <i>IEEE Access</i> , 2022, 10, 126990-127004.	2.6	4
162	Experimental evidence for temporal uncoupling of brain A β deposition and neurodegenerative sequelae. <i>Nature Communications</i> , 2022, 13, .	5.8	6
163	Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology. <i>Nature Aging</i> , 2022, 2, 1138-1144.	5.3	19
164	Lateral flow assays for detection of disease biomarkers. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, 225, 115206.	1.4	9
165	Current Pharmacotherapy and Multi-Target Approaches for Alzheimer's Disease. <i>Pharmaceuticals</i> , 2022, 15, 1560.	1.7	18
166	Methods for the isolation and analysis of A β from postmortem brain. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	0
167	Animal models in Alzheimer's disease: Biological plausibility and mood disorders. <i>Neurology Perspectives</i> , 2023, 3, 100110.	0.2	1
168	Conjugates of Tacrine and Salicylic Acid Derivatives as New Promising Multitarget Agents for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2285.	1.8	7
169	Multifactorial glial responses and their contributions to Alzheimer's disease continuum. <i>Clinical and Experimental Neuroimmunology</i> , 2023, 14, 82-91.	0.5	1
170	Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer's disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay. <i>Nano Research</i> , 2023, 16, 7459-7469.	5.8	9

#	ARTICLE	IF	CITATIONS
171	Effect of Ovocystatin on Amyloid β 1-42 Aggregation in Vitro Studies. International Journal of Molecular Sciences, 2023, 24, 5433.	1.8	2
173	Volume changes of hippocampal and amygdala subfields in patients with mild cognitive impairment and Alzheimer's disease. Acta Neurologica Belgica, 2023, 123, 1381-1393.	0.5	3
187	Natural molecules in neuroprotection and neurotoxicity in neurodegenerative diseases. , 2024, , 3-28.		0